Holds one active US DMF for pyridostigmine, filing since 1984. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 6 markets.
Holds 2 active US DMFs and one valid CEP for pyridostigmine, filing since 2020. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF and one valid CEP for pyridostigmine, filing since 2002. Its 2022 FDA inspection closed as VAI.
Holds 2 active US DMFs for pyridostigmine, filing since 2026. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one valid CEP for pyridostigmine, filing since 2024. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF for pyridostigmine, filing since 1993.
Holds one active US DMF for pyridostigmine, filing since 2024.
Holds one active US DMF for pyridostigmine, filing since 2024. Its 2024 FDA inspection closed as OAI, and its GMP is recognised in 3 markets.
Registered with SFDA (Saudi Arabia) for pyridostigmine.
Registered with DAV (Vietnam) for pyridostigmine. Its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free